Alliance for Multispecialty Research, LLC. | Norfolk, VA

Research site

(Unclaimed)

Location

6161 Kemspsville Circle Suite 225, Norfolk, Virginia, United States of America

Site insights

Top conditions

Top treatments

MK-0616

Cytisinicline

Retatrutide

Dihydroergotamine

JATENZO®

Etrasimod

Parent organization

This site is a part of Alliance for Multispecialty Research, LLC.

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 23 total trials

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men...

Active, not recruiting

Hypogonadism

Drug: Jatenzo

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

The purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are:* safe; and* how these vaccines produce a...

Active, not recruiting

Influenza, Human

Biological: Influenza ModRNA Vaccine

Biological: Quadrivalent Influenza Vaccine (QIV)

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main o...

Enrolling

Epstein-Barr Virus Infection

Biological: mRNA-1189

Biological: Placebo

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia....

Active, not recruiting

Hypercholesterolemia

Familial Hypercholesterolemia

Drug: Enlicitide Decanoate

Drug: Placebo

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates tar...

Active, not recruiting

COVID-19

SARS-CoV-2 Infection

Biological: BNT162b2 (Omi XBB.1.5)

Biological: BNT162b2 (Omi JN.1)

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling

Arteriosclerosis

Hypercholesterolaemia

Drug: Placebo

Drug: Enlicitide Decanoate

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunoge...

Enrolling

Chikungunya Virus Infection

Biological: Placebo booster

Biological: CHIKV VLP vaccine booster

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed...

Enrolling

Hypercholesterolemia

Drug: Enlicitide Decanoate

Safety Study of Cytisinicline in Adult Combustible And/or E-cigarette Smokers (ORCA-OL)

Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the U...

Active, not recruiting

Vaping Cessation

Smoking Cessation

Drug: Cytisinicline

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo